Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancer
dc.contributor.author | Gray, Phillip J. | en_US |
dc.contributor.author | Paly, Jonathan J. | en_US |
dc.contributor.author | Yeap, Beow Y. | en_US |
dc.contributor.author | Sanda, Martin G. | en_US |
dc.contributor.author | Sandler, Howard. M. | en_US |
dc.contributor.author | Michalski, Jeff M. | en_US |
dc.contributor.author | Talcott, James A. | en_US |
dc.contributor.author | Coen, John J. | en_US |
dc.contributor.author | Hamstra, Daniel A. | en_US |
dc.contributor.author | Shipley, William U. | en_US |
dc.contributor.author | Hahn, Stephen M. | en_US |
dc.contributor.author | Zietman, Anthony L. | en_US |
dc.contributor.author | Bekelman, Justin E. | en_US |
dc.contributor.author | Efstathiou, Jason A. | en_US |
dc.date.accessioned | 2013-05-02T19:35:08Z | |
dc.date.available | 2014-07-01T15:53:31Z | en_US |
dc.date.issued | 2013-05-01 | en_US |
dc.identifier.citation | Gray, Phillip J.; Paly, Jonathan J.; Yeap, Beow Y.; Sanda, Martin G.; Sandler, Howard. M.; Michalski, Jeff M.; Talcott, James A.; Coen, John J.; Hamstra, Daniel A.; Shipley, William U.; Hahn, Stephen M.; Zietman, Anthony L.; Bekelman, Justin E.; Efstathiou, Jason A. (2013). "Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancer ." Cancer 119(9): 1729-1735. <http://hdl.handle.net/2027.42/97476> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/97476 | |
dc.description.abstract | BACKGROUND: Recent studies have suggested differing toxicity patterns for patients with prostate cancer who receive treatment with 3‐dimensional conformal radiotherapy (3DCRT), intensity‐modulated radiotherapy (IMRT), or proton beam therapy (PBT). METHODS: The authors reviewed patient‐reported outcomes data collected prospectively using validated instruments that assessed bowel and urinary quality of life (QOL) for patients with localized prostate cancer who received 3DCRT (n = 123), IMRT (n = 153) or PBT (n = 95). Clinically meaningful differences in mean QOL scores were defined as those exceeding half the standard deviation of the baseline mean value. Changes from baseline were compared within groups at the first post‐treatment follow‐up (2‐3 months from the start of treatment) and at 12 months and 24 months. RESULTS: At the first post‐treatment follow‐up, patients who received 3DCRT and IMRT, but not those who received PBT, reported a clinically meaningful decrement in bowel QOL. At 12 months and 24 months, all 3 cohorts reported clinically meaningful decrements in bowel QOL. Patients who received IMRT reported clinically meaningful decrements in the domains of urinary irritation/obstruction and incontinence at the first post‐treatment follow‐up. At 12 months, patients who received PBT, but not those who received IMRT or 3DCRT, reported a clinically meaningful decrement in the urinary irritation/obstruction domain. At 24 months, none of the 3 cohorts reported clinically meaningful changes in urinary QOL. CONCLUSIONS: Patients who received 3DCRT, IMRT, or PBT reported distinct patterns of treatment‐related QOL. Although the timing of toxicity varied between the cohorts, patients reported similar modest QOL decrements in the bowel domain and minimal QOL decrements in the urinary domains at 24 months. Prospective randomized trials are needed to further examine these differences. Cancer 2013. © 2013 American Cancer Society. Prostate cancer patients who receive 3‐dimensional conformal radiotherapy, intensity‐modulated radiotherapy, or proton beam therapy report distinct patterns of treatment‐related quality of life. Although the timing of toxicity varies between cohorts, patients report similar modest quality‐of‐life decrements in the bowel domain and minimal QOL decrements in the urinary domains at 24 months. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Quality of Life | en_US |
dc.subject.other | 3‐Dimensional Conformal Radiotherapy | en_US |
dc.subject.other | Intensity‐Modulated Radiotherapy | en_US |
dc.subject.other | Patient Reported Outcomes | en_US |
dc.subject.other | Prostate Cancer | en_US |
dc.subject.other | Proton Therapy | en_US |
dc.title | Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancer | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Harvard Radiation Oncology Program, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 3, Boston, MA 02114 | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania | en_US |
dc.contributor.affiliationother | Hartford Radiation Oncology Associates, Hartford, Connecticut | en_US |
dc.contributor.affiliationother | Continuum Cancer Care Consortium, New York, New York | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Cedars‐Sinai Medical Center, Los Angeles, California | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts | en_US |
dc.identifier.pmid | 23436283 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/97476/1/27956_ftp.pdf | |
dc.identifier.doi | 10.1002/cncr.27956 | en_US |
dc.identifier.source | Cancer | en_US |
dc.identifier.citedreference | Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose‐volume effects in radiation‐induced rectal injury. Int J Radiat Oncol Biol Phys. 2010; 76 ( 3 suppl ): S123 – S129. | en_US |
dc.identifier.citedreference | Coen JJ, Bae K, Zietman AL, et al. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology phase II study 03‐12. Int J Radiat Oncol Biol Phys. 2011; 81: 1005 – 1009. | en_US |
dc.identifier.citedreference | Bekelman JE, Mitra N, Efstathiou J, et al. Outcomes after intensity‐modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2011; 81: e325 – e334. | en_US |
dc.identifier.citedreference | Dinan MA, Robinson TJ, Zagar TM, et al. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999‐2007. Int J Radiat Oncol Biol Phys. 2012; 82: e781 – e786. | en_US |
dc.identifier.citedreference | Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011; 29: 1517 – 1524. | en_US |
dc.identifier.citedreference | Efstathiou JA, Trofimov AV, Zietman AL. Life, liberty, and the pursuit of protons: an evidence‐based review of the role of particle therapy in the treatment of prostate cancer. Cancer J. 2009; 15: 312 – 318. | en_US |
dc.identifier.citedreference | Kim S, Shen S, Moore DF, et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol. 2011; 60: 908 – 916. | en_US |
dc.identifier.citedreference | Konski A, Speier W, Hanlon A, Beck JR, Pollack A. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol. 2007; 25: 3603 – 3608. | en_US |
dc.identifier.citedreference | Sheets NC, Goldin GH, Meyer AM, et al. Intensity‐modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012; 307: 1611 – 1620. | en_US |
dc.identifier.citedreference | Lodge M, Pijls‐Johannesma M, Stirk L, Munro AJ, De Ruysscher D, Jefferson T. A systematic literature review of the clinical and cost‐effectiveness of hadron therapy in cancer. Radiother Oncol. 2007; 83: 110 – 122. | en_US |
dc.identifier.citedreference | Moya del Pina B. Proton therapy for cancer: a new technology brief. Available at: http://www.cancer.gov/aboutnci/ncicancerbulletin/archive/2009/090809/page8. [Accessed November 1, 2012 ]. | en_US |
dc.identifier.citedreference | Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008; 148: 435 – 448. | en_US |
dc.identifier.citedreference | Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care. 2001; 39: 1118 – 1130. | en_US |
dc.identifier.citedreference | Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health‐related quality of life in men with prostate cancer. Urology. 2000; 56: 899 – 905. | en_US |
dc.identifier.citedreference | Coen JJ, Paly JJ, Niemierko A, et al. Long‐term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82: e201 – e209. | en_US |
dc.identifier.citedreference | Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate‐cancer survivors. N Engl J Med. 2008; 358: 1250 – 1261. | en_US |
dc.identifier.citedreference | Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003; 21: 3979 – 3986. | en_US |
dc.identifier.citedreference | Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health‐related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003; 41: 582 – 592. | en_US |
dc.identifier.citedreference | Alicikus ZA, Yamada Y, Zhang Z, et al. Ten‐year outcomes of high‐dose, intensity‐modulated radiotherapy for localized prostate cancer. Cancer. 2011; 117: 1429 – 1437. | en_US |
dc.identifier.citedreference | Ferrer M, Suarez JF, Guedea F, et al. Health‐related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 72: 421 – 432. | en_US |
dc.identifier.citedreference | Hoppe BS, Nichols RC, Henderson RH, et al. Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer. 2012; 118: 4619 – 4626. | en_US |
dc.identifier.citedreference | Pederson AW, Fricano J, Correa D, Pelizzari CA, Liauw SL. Late toxicity after intensity‐modulated radiation therapy for localized prostate cancer: an exploration of dose‐volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Int J Radiat Oncol Biol Phys. 2012; 82: 235 – 241. | en_US |
dc.identifier.citedreference | Pinkawa M, Piroth MD, Fischedick K, et al. Self‐assessed bowel toxicity after external beam radiotherapy for prostate cancer—predictive factors on irritative symptoms, incontinence and rectal bleeding [serial online]. Radiat Oncol. 2009; 4: 36. | en_US |
dc.identifier.citedreference | Sandler HM, Liu PY, Dunn RL, Khan DC, Tropper SE, Sanda MG, et al. Reduction in patient‐reported acute morbidity in prostate cancer patients treated with 81‐Gy intensity‐modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study. Urology. 2010; 75: 1004 – 1008. | en_US |
dc.identifier.citedreference | Michalski JM, Yan Y, Watkins‐Bruner D, et al. Preliminary analysis of 3D‐CRT vs IMRT on the high dose arm of the RTOG 0126 Prostate Cancer Trial: toxicity report. Int J Radiat Oncol Biol Phys. 2011; 81: S1 – S2. | en_US |
dc.identifier.citedreference | Watkins Bruner D, Hunt D, et al. Preliminary analysis of 3D‐CRT vs IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial: patient reported outcomes. J Radiat Oncol Biol Phys. 2011; 81: S44 – S44. | en_US |
dc.identifier.citedreference | Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010; 76 ( 3 suppl ): S10 – S19. | en_US |
dc.identifier.citedreference | Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007; 69: 444 – 453. | en_US |
dc.identifier.citedreference | Schwarz M, Pierelli A, Fiorino C, et al. Helical tomotherapy and intensity modulated proton therapy in the treatment of early stage prostate cancer: a treatment planning comparison. Radiother Oncol. 2011; 98: 74 – 80. | en_US |
dc.identifier.citedreference | Dias RS, Giordani AJ, Souhami L, Segreto RA, Segreto HR. Rectal planning risk volume correlation with acute and late toxicity in 3‐dimensional conformal radiation therapy for prostate cancer. Technol Cancer Res Treat. 2011; 10: 585 – 590. | en_US |
dc.identifier.citedreference | Valdagni R, Rancati T, Fiorino C, et al. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D‐CRT. Int J Radiat Oncol Biol Phys. 2008; 71: 1065 – 1073. | en_US |
dc.identifier.citedreference | Vavassori V, Fiorino C, Rancati T, et al. Predictors for rectal and intestinal acute toxicities during prostate cancer high‐dose 3D‐CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys. 2007; 67: 1401 – 1410. | en_US |
dc.identifier.citedreference | Rancati T, Fiorino C, Fellin G, et al. Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer. Radiother Oncol. 2011; 100: 124 – 130. | en_US |
dc.identifier.citedreference | Skwarchuk MW, Jackson A, Zelefsky MJ, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose‐response. Int J Radiat Oncol Biol Phys. 2000; 47: 103 – 113. | en_US |
dc.identifier.citedreference | Karlsdottir A, Muren LP, Wentzel‐Larsen T, Dahl O. Late gastrointestinal morbidity after 3‐dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. Int J Radiat Oncol Biol Phys. 2008; 70: 1478 – 1486. | en_US |
dc.identifier.citedreference | Jackson A, Skwarchuk MW, Zelefsky MJ, et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose‐volume histograms. Int J Radiat Oncol Biol Phys. 2001; 49: 685 – 698. | en_US |
dc.identifier.citedreference | Nguyen PL, Chen RC, Hoffman KE, et al. Rectal dose‐volume histogram parameters are associated with long‐term patient‐reported gastrointestinal quality of life after conventional and high‐dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int J Radiat Oncol Biol Phys. 2010; 78: 1081 – 1085. | en_US |
dc.identifier.citedreference | Tucker SL, Dong L, Michalski JM, et al. Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from Radiation Therapy Oncology Group protocol 94‐06. Int J Radiat Oncol Biol Phys. 2012; 84: 390 – 395. | en_US |
dc.identifier.citedreference | Fiorino C, Fellin G, Rancati T, Vavassori V, Bianchi C, Borca VC, et al. Clinical and dosimetric predictors of late rectal syndrome after 3D‐CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys. 2008; 70: 1130 – 1137. | en_US |
dc.identifier.citedreference | Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, et al. Proton versus intensity‐modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst 2013; 105: 25 – 32. | en_US |
dc.identifier.citedreference | Potosky AL, Warren JL, Riedel ER, Klabunde CN, Earle CC, Begg CB. Measuring complications of cancer treatment using the SEER‐Medicare data. Med Care. 2002; 40 ( 8 suppl ): IV‐62 – IV‐68. | en_US |
dc.identifier.citedreference | Muanza TM, Albert PS, Smith S, et al. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2005; 62: 1316 – 1321. | en_US |
dc.identifier.citedreference | Hovdenak N, Karlsdottir A, Sorbye H, Dahl O. Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncol. 2003; 42: 741 – 748. | en_US |
dc.identifier.citedreference | Shah A, Efstathiou JA, Paly JJ, et al. Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity‐modulated radiotherapy versus proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 83: e19 – e19. | en_US |
dc.identifier.citedreference | Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional‐dose with high‐dose conformal radiation therapy in early stage adenocarcinoma of the prostate: long‐term results from Proton Radiation Oncology Group/American College of Radiology 95‐09. J Clin Oncol. 2010; 28: 1106 – 1111. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.